INNATE PHARMA: Launch of IND-Enabling studies for IPH4102
*IPH4102 is a first-in-class drug candidate targeting KIR3DL2, a receptor
specifically expressed by some rare forms of cancer
*It is developed in an orphan disease, cutaneous T-cell lymphomas, and
especially their aggressive forms: Sezary Syndrome and Transformed Mycosis
*An investigational new drug (IND) application should be submitted in late
*Innate Pharma intends to develop IPH4102 as a proprietary program
MARSEILLE, France, Nov. 8, 2013 (GLOBE NEWSWIRE) -- Innate Pharma SA (the
"Company" - Euronext Paris: FR0010331421 - IPH), the innate immunity company
developing first-in-class drug candidates for cancer and inflammatory
diseases, announced today that it had selected and qualified the IPH4102 drug
candidate for further development.
IPH4102 is a first-in-class cytotoxic antibody developed in some types of
KIR3DL2-expressing cancers, such as the Sezary Syndrome ("SS") and Transformed
Mycosis Fungoides ("TMF"), which are aggressive forms of cutaneous T-cell
lymphomas. IND-enabling studies and industrial production of the molecule have
begun. The IND application is expected to be submitted in late 2014.
Professor Martine Bagot, Head of the Dermatology Department at the Saint-Louis
Hospital in Paris, France, said: "We discovered the KIR3DL2 target with
Professor Bensussan's team and worked together with Innate Pharma for several
years to design this drug candidate. The unmet need in SS and TMF is huge. Due
to its original target specifically expressed by the tumor cells, IPH4102 has
a unique potential for being both very active and well tolerated".
"We plan to develop IPH4102 in cutaneous T-cell lymphomas expressing KIR3DL2
in close collaboration with referral international centres such as the
Saint-Louis Hospital" added Marcel Rozencweig, Chief Medical Officer at Innate
Pharma. "These are orphan diseases and their more devastating forms could
particularly benefit from a treatment using IPH4102".
A poster on IPH4102 is presented today at the Annual Meeting of the Society
for Immunotherapy of Cancer (SITC, 7 - 10 November 2013, National Harbor, MD,
United States): "Novel therapeutic and diagnostic antibodies against KIR3DL2,
a unique tumour antigen expressed on subtypes of T-Cell Lymphomas", from 1:00
to 2:00 pm and from 6:15 to 7:15 pm, Poster 49.
About IPH4102, Sezary Syndrome and Transformed Mycosis Fungoides:
KIR3DL2 is an inhibiting receptor of the KIR superfamily, normally expressed
on a minor fraction of normal NK cells but specifically expressed in certain
aggressive forms of the orphan indication of cutaneous T-cell lymphomas, such
as Transformed Mycosis Fungoides (TMF) and Sezary Syndrome (SS).
TMF and SS are the most severe forms of cutaneous T-cell lymphomas with a
median survival of 2 to 3 years for their advanced stages.
IPH4102 is a humanized cytotoxic antibody which targets and destroys cells
expressing KIR3DL2. It selectively binds KIR3DL2 and has demonstrated a high
level of efficacy in various pre-clinical models. Innate Pharma owns recently
filed patent applications directed to anti-KIR3DL2 antibodies, including
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drug candidates for cancer and inflammatory diseases.
The Company specializes in the development of novel monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its innovative approaches have led to licensing agreements with Novo
Nordisk A/S and Bristol-Myers Squibb.
Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate
Pharma is based in Marseilles, France, and had 84 employees as at September
Learn more about Innate Pharma at www.innate-pharma.com.
Practical Information about Innate Pharma shares:
ISIN code FR0010331421
Ticker code IPH
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ
from those contained in the forward-looking statements, please refer to the
Risk Factors ("Facteurs de Risque") section of the Document de Reference
prospectus filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.
Press Release: http://hugin.info/155662/R/1741705/585277.pdf
CONTACT: For additional information, please contact:
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87
Mob.: +33 (0)6 26 94 18 53
Press spacebar to pause and continue. Press esc to stop.